MARKET

OCUL

OCUL

Ocular
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.930
-0.390
-11.75%
After Hours: 2.850 -0.08 -2.73% 19:49 11/11 EST
OPEN
3.300
PREV CLOSE
3.320
HIGH
3.330
LOW
2.750
VOLUME
976.87K
TURNOVER
--
52 WEEK HIGH
6.88
52 WEEK LOW
2.350
MARKET CAP
138.28M
P/E (TTM)
-1.6434
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OCUL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

OCUL News

  • Ocular Therapeutix launches cost-cutting initiative; shares up 3% after hours
  • seekingalpha.3d ago
  • Ocular Therapeutix launches cost-cutting initiative; shares up 3% after hours
  • Seeking Alpha - Article.3d ago
  • Ocular Therapeutix Announces Strategic Update and Operational Restructuring
  • Business Wire.3d ago
  • Key events next week - healthcare
  • Seeking Alpha - Article.3d ago

More

Industry

Medical Equipment, Supplies & Distribution
-0.15%
Healthcare Equipment & Supplies
-0.25%

Hot Stocks

Name
Price
%Change

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
More

Webull offers Ocular Therapeutix Inc (OCUL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.